Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.010 AlteredExpression disease BEFREE It is presumed that the anti-apoptotic function of IFI6 is expressed by regulating the rheostatic balance between bcl-2/bax expression and inhibition of Δψ(m) depolarization during DENV infection of vascular endothelial cells(VECs). 26244642 2015
Entrez Id: 637
Gene Symbol: BID
BID
0.010 Biomarker disease BEFREE Viral genotyping determined by phylogenetic analysis of the complete envelope gene sequences demonstrated that the DENV-2 isolates from Guatemala and Honduras fell into the American/Asian Genotype III, and were most closely related to DENV-2/NI/BID-V2683-1999 isolated from a dengue case in Nicaragua in 1999; and the DENV-4 F07-076 isolate from Honduras belonged to genotype II, and was most closely related to DENV-4/US/BID-V1093/1998 isolated from Puerto Rico in 1998. 21234665 2011
Entrez Id: 684
Gene Symbol: BST2
BST2
0.010 AlteredExpression disease BEFREE We found that expression of BST2 did not affect the efficiency of DENV infection and intracellular replication. 23236425 2012
Entrez Id: 4076
Gene Symbol: CAPRIN1
CAPRIN1
0.010 Biomarker disease BEFREE Correction: G3BP1, G3BP2 and CAPRIN1 Are Required for Translation of Interferon Stimulated mRNAs and Are Targeted by a Dengue Virus Non-coding RNA. 28350882 2017
Entrez Id: 847
Gene Symbol: CAT
CAT
0.010 Biomarker disease BEFREE However, catalase knockdown reduced Dengue 4, but not Zika, infection prevalence (percent of infected midguts). 28379952 2017
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.020 Biomarker disease BEFREE This study was aimed at evaluating the expression of the CC-chemokines MIP-1α/CCL3 and MCP-1/CCL2 in peripheral blood leukocytes using an ex vivo model resembling dengue infection in vivo, in subjects with a well characterized dengue immune background, due to the exceptional Cuban epidemiological situation in dengue. 20650649 2010
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.020 GeneticVariation disease BEFREE Significantly higher frequency of R/R genotype of FCGR2A p.R131H was observed in DEN cases with thrombocytopenia (TP) while the G/G genotype of CCL2 c.-2518 A > G was observed only in DEN cases with TP (p < 0.005). 26429304 2015
Entrez Id: 6348
Gene Symbol: CCL3
CCL3
0.020 Biomarker disease BEFREE This study was aimed at evaluating the expression of the CC-chemokines MIP-1α/CCL3 and MCP-1/CCL2 in peripheral blood leukocytes using an ex vivo model resembling dengue infection in vivo, in subjects with a well characterized dengue immune background, due to the exceptional Cuban epidemiological situation in dengue. 20650649 2010
Entrez Id: 6348
Gene Symbol: CCL3
CCL3
0.020 AlteredExpression disease BEFREE CCR1 and CCL3/MIP-1α gene expression was higher in patients with secondary infection during critical days of the dengue disease, while the increase in RANTES expression started earlier than the observed for CCR1 and CCL3/MIP-1α. 24157267 2014
Entrez Id: 6351
Gene Symbol: CCL4
CCL4
0.020 AlteredExpression disease BEFREE Plasma cytokine profiling (8 DF, 8 DHF, and 8 HC) on two consecutive time points, at day 0 (day of admission) and days 5-7, found significant elevation in IL-1RA, IL-7, TNF-α, MCP1-MCAF, and MIP-1β levels, but only in the DHF cases, which is the severe disease, and not in DF, compared with HCs (p < 0.05). 29091011 2017
Entrez Id: 6351
Gene Symbol: CCL4
CCL4
0.020 Biomarker disease BEFREE Based on the dengue-2 model, variables with the highest odds ratio were AT-lag1 and RH-lag0 indicating an 8.9 and 18.1 times greater probability of a moderate MID, respectively. 28700047 2017
Entrez Id: 388372
Gene Symbol: CCL4L1
CCL4L1
0.020 AlteredExpression disease BEFREE Plasma cytokine profiling (8 DF, 8 DHF, and 8 HC) on two consecutive time points, at day 0 (day of admission) and days 5-7, found significant elevation in IL-1RA, IL-7, TNF-α, MCP1-MCAF, and MIP-1β levels, but only in the DHF cases, which is the severe disease, and not in DF, compared with HCs (p < 0.05). 29091011 2017
Entrez Id: 388372
Gene Symbol: CCL4L1
CCL4L1
0.020 Biomarker disease BEFREE Based on the dengue-2 model, variables with the highest odds ratio were AT-lag1 and RH-lag0 indicating an 8.9 and 18.1 times greater probability of a moderate MID, respectively. 28700047 2017
Entrez Id: 9560
Gene Symbol: CCL4L2
CCL4L2
0.020 Biomarker disease BEFREE Based on the dengue-2 model, variables with the highest odds ratio were AT-lag1 and RH-lag0 indicating an 8.9 and 18.1 times greater probability of a moderate MID, respectively. 28700047 2017
Entrez Id: 9560
Gene Symbol: CCL4L2
CCL4L2
0.020 AlteredExpression disease BEFREE Plasma cytokine profiling (8 DF, 8 DHF, and 8 HC) on two consecutive time points, at day 0 (day of admission) and days 5-7, found significant elevation in IL-1RA, IL-7, TNF-α, MCP1-MCAF, and MIP-1β levels, but only in the DHF cases, which is the severe disease, and not in DF, compared with HCs (p < 0.05). 29091011 2017
Entrez Id: 6352
Gene Symbol: CCL5
CCL5
0.040 Biomarker disease BEFREE The reporter gene was optimally activated by dengue-2 virus when the RANTES promoter contains the region from the transcription starting site (+1) to the nucleotide at the -181 position. 11022000 2000
Entrez Id: 6352
Gene Symbol: CCL5
CCL5
0.040 Biomarker disease BEFREE The results, therefore, suggest the significance of RANTES-CCR5 axis deregulation and resulting altered immunomodulation in Dengue pathogenesis, and holds prognostic and therapeutic significance. 31368534 2019
Entrez Id: 6352
Gene Symbol: CCL5
CCL5
0.040 Biomarker disease BEFREE We addressed the role of CCR1 and its ligands CCL3/MIP-1α and CCL5/RANTES in dengue infection using three different approaches: an ex vivo model exploring memory immune response in subjects with a well characterized dengue immune background, an in vivo study in patients with primary or secondary dengue infection, and an approach in fatal dengue. 24157267 2014
Entrez Id: 6352
Gene Symbol: CCL5
CCL5
0.040 Biomarker disease BEFREE An elevated levels of cytokines IL6 and IL10 chemokine IL8 and CXCL10 along with decreased RANTES were found in the patients with Severe Dengue as compared to mild forms of dengue (p < 0.0001) during 3-6 days of infections. 30395811 2019
Entrez Id: 1230
Gene Symbol: CCR1
CCR1
0.010 Biomarker disease BEFREE CCR1 and CCL3/MIP-1α gene expression was higher in patients with secondary infection during critical days of the dengue disease, while the increase in RANTES expression started earlier than the observed for CCR1 and CCL3/MIP-1α. 24157267 2014
Entrez Id: 1234
Gene Symbol: CCR5
CCR5
0.030 Biomarker disease BEFREE Using an immunocompetent mouse model of DENV-2 infection we found that CCR5(-/-) mice were resistant to lethal infection, presenting at least 100-fold reduction of viral load in target organs and significant reduction in disease severity. 25939314 2015
Entrez Id: 1234
Gene Symbol: CCR5
CCR5
0.030 Biomarker disease BEFREE The results, therefore, suggest the significance of RANTES-CCR5 axis deregulation and resulting altered immunomodulation in Dengue pathogenesis, and holds prognostic and therapeutic significance. 31368534 2019
Entrez Id: 1234
Gene Symbol: CCR5
CCR5
0.030 GeneticVariation disease BEFREE In a Western Australian population with the same frequency of CCR5Δ32 (0.08) as that found in southern Europe there was no significant difference in CCR5Δ32 allele frequency between returned travellers with and without dengue (p = 0.82, OR = 0.86, 95% CI = 0.35-2.1). 24607451 2014
Entrez Id: 929
Gene Symbol: CD14
CD14
0.010 Biomarker disease BEFREE Furthermore, depletion of CD14+ monocytes prior to DV inoculation abrogated the detection of infected cells, and the addition of monoclonal antibodies to either FcgammaRI (CD64) or FcgammaRII (CD32) led to a 50-70% reduction in antibody-dependent enhancement (ADE) of DV infection. 18041019 2008
Entrez Id: 30835
Gene Symbol: CD209
CD209
0.400 GeneticVariation disease BEFREE Results revealed a significantly higher frequency of 'G' allele and 'G/G' genotype of rs2287886 and A-A-G haplotype of CD209 gene in DEN compared to healthy controls [For 'G/G' genotype, P=0.0072, Odds ratio (OR) 2.43; For A-A-G haplotype, P=0.0033, OR 2]. 23624202 2013